

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 February 2023 (02.02.2023)



(10) International Publication Number
WO 2023/010078 A1

(51) International Patent Classification:

C07D 403/12 (2006.01) A61P 25/18 (2006.01)
C07D 403/14 (2006.01) A61P 25/30 (2006.01)
C07D 495/04 (2006.01) A61K 31/497 (2006.01)
A61P 25/14 (2006.01) A61K 31/506 (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:

PCT/US2022/074257

(22) International Filing Date:

28 July 2022 (28.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/227,467 30 July 2021 (30.07.2021) US

(71) Applicant: **NEUROCRINE BIOSCIENCES, INC.**
[US/US]; 12780 El Camino Real, San Diego, California
92130 (US).

(72) Inventors: **HARRIOTT, Nicole**; c/o Neurocrine Bio-
sciences, Inc., 12780 El Camino Real, San Diego, Califor-
nia 92130 (US). **PAGANO, Nicholas**; c/o Neurocrine Bio-
sciences, Inc., 12780 El Camino Real, San Diego, Califor-
nia 92130 (US). **LEY, Corinne Rose**; c/o Neurocrine Bio-
sciences, Inc., 12780 El Camino Real, San Diego, Califor-
nia 92130 (US).

(74) Agent: **DAVEY, Evan A.** et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE



(57) Abstract: The present invention relates to compounds of Formula (Ia), pharmaceutically acceptable salts of compounds of Formula (Ia), and pharmaceutical compositions thereof that modulate the activity of the muscarinic acetylcholine receptor M4. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present invention are directed to methods useful in the treatment or prophylaxis of a neurological disease, disorder, or symptom, and conditions related thereto.

WO 2023/010078 A1